Review article · 2023 · Open access

Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks

Yong Peng, Hong Jin, Ya-hui Xue, Quan Chen, Shunyu Yao, Miao‐qiao Du, Shu Liu

Frontiers in Aging Neuroscience, 15, 1206572 · Published 3 August 2023 · DOI 10.3389/fnagi.2023.1206572

Free PDFView at the publisherCite this paper

In brief

“Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks” is a 2023 review article by Yong Peng and 6 co-authors, published in Frontiers in Aging Neuroscience. OpenAlex counts 196 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Aging Neuroscience.

Citations
196
Most cited in
2025 (76)
Field-weighted impact
5.32
References
178
Authors
7

Abstract

Alzheimer's disease (AD) is the most common chronic neurodegenerative disease worldwide. It causes cognitive dysfunction, such as aphasia and agnosia, and mental symptoms, such as behavioral abnormalities; all of which place a significant psychological and economic burden on the patients' families. No specific drugs are currently available for the treatment of AD, and the current drugs for AD only delay disease onset and progression. The pathophysiological basis of AD involves abnormal deposition of beta-amyloid protein (Aβ), abnormal tau protein phosphorylation, decreased activity of acetylcholine content, glutamate toxicity, autophagy, inflammatory reactions, mitochondria-targeting, and multi-targets. The US Food and Drug Administration (FDA) has approved five drugs for clinical use: tacrine, donepezil, carbalatine, galantamine, memantine, and lecanemab. We have focused on the newer drugs that have undergone clinical trials, most of which have not been successful as a result of excessive clinical side effects or poor efficacy. Although aducanumab received rapid approval from the FDA on 7 June 2021, its long-term safety and tolerability require further monitoring and confirmation. In this literature review, we aimed to explore the possible pathophysiological mechanisms underlying the occurrence and development of AD. We focused on anti-Aβ and anti-tau drugs, mitochondria-targeting and multi-targets, commercially available drugs, bottlenecks encountered in drug development, and the possible targets and therapeutic strategies for future drug development. We hope to present new concepts and methods for future drug therapies for AD.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S., Du, M., & Liu, S. (2023). Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks. Frontiers in Aging Neuroscience, 15, 1206572. https://doi.org/10.3389/fnagi.2023.1206572

MLA 9

Peng, Yong, et al. “Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks.” Frontiers in Aging Neuroscience, vol. 15, 2023, p. 1206572. https://doi.org/10.3389/fnagi.2023.1206572.

Chicago

Peng, Yong, Hong Jin, Ya-hui Xue, Quan Chen, Shunyu Yao, Miao‐qiao Du, and Shu Liu. 2023. “Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks.” Frontiers in Aging Neuroscience 15: 1206572. https://doi.org/10.3389/fnagi.2023.1206572.

Harvard

Peng, Y. et al. (2023) ‘Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks’, Frontiers in Aging Neuroscience, 15, p. 1206572. doi:10.3389/fnagi.2023.1206572.

IEEE

Y. Peng et al., “Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks,” Frontiers in Aging Neuroscience, vol. 15, p. 1206572, 2023, doi: 10.3389/fnagi.2023.1206572.

BibTeX

@article{peng2023current,
  title     = {{Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks}},
  author    = {Peng, Yong and Jin, Hong and Xue, Ya-hui and Chen, Quan and Yao, Shunyu and Du, Miao‐qiao and Liu, Shu},
  journal   = {Frontiers in Aging Neuroscience},
  year      = {2023},
  volume    = {15},
  pages     = {1206572},
  doi       = {10.3389/fnagi.2023.1206572},
  url       = {https://doi.org/10.3389/fnagi.2023.1206572}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202211
202366
20245757
20257676
20265656

Its field-weighted citation impact is 5.32: it has been cited 5.32 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • anti-amyloid drugs
  • amyloid-beta
  • tau hyperphosphorylation
  • aducanumab
  • lecanemab
  • tacrine
  • donepezil

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S., Du, M., & Liu, S. (2023). Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks. Frontiers in Aging Neuroscience, 15, 1206572. https://doi.org/10.3389/fnagi.2023.1206572

How many times has this paper been cited?

196 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Frontiers in Aging Neuroscience.

Who wrote this paper?

Yong Peng, Hong Jin, Ya-hui Xue, Quan Chen, Shunyu Yao, Miao‐qiao Du, Shu Liu.

What is the DOI of this paper?

10.3389/fnagi.2023.1206572. The permanent link is https://doi.org/10.3389/fnagi.2023.1206572.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.